{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:52:35Z","timestamp":1779324755645,"version":"3.51.4"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Discovery Foundation, South Africa"},{"name":"South African National Department of Health"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Virology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jcv.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,6,14]],"date-time":"2019-06-14T15:29:12Z","timestamp":1560526152000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission"],"prefix":"10.1016","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0216-6701","authenticated-orcid":false,"given":"Oladele Vincent","family":"Adeniyi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikwelu Larry","family":"Obi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Ter","family":"Goon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benson","family":"Iweriebor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony Idowu","family":"Ajayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony","family":"Okoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"January (1)","key":"10.1016\/j.jcv.2019.06.003_bib0005","doi-asserted-by":"crossref","first-page":"18944","DOI":"10.7448\/IAS.17.1.18944","article-title":"Do HIV\u20101 non\u2010B subtypes differentially impact resistance mutations and clinical disease progression in treated populations? Evidence from a systematic review","volume":"17","author":"Bhargava","year":"2014","journal-title":"J. Int. AIDS Soc."},{"issue":"May (5)","key":"10.1016\/j.jcv.2019.06.003_bib0010","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(15)00536-8","article-title":"Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study","volume":"16","author":"Gregson","year":"2016","journal-title":"Lancet Infect. Dis."},{"issue":"March (3)","key":"10.1016\/j.jcv.2019.06.003_bib0015","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2018","journal-title":"Lancet Infect. Dis."},{"issue":"January (66)","key":"10.1016\/j.jcv.2019.06.003_bib0020","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ijid.2017.10.020","article-title":"HIV drug resistance following a decade of the free antiretroviral therapy programme in India: a review","volume":"1","author":"Karade","year":"2018","journal-title":"Int. J. Infect. Dis."},{"issue":"July (12)","key":"10.1016\/j.jcv.2019.06.003_bib0025","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1097\/QAD.0b013e32836158b0","article-title":"HIV transmission and 24-month survival in a randomized trial of HAART to prevent MTCT during pregnancy and breastfeeding in Botswana (the Mma Bana Study)","volume":"27","author":"Shapiro","year":"2013","journal-title":"AIDS"},{"issue":"November (18)","key":"10.1016\/j.jcv.2019.06.003_bib0030","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1511691","article-title":"Benefits and risks of antiretroviral therapy for perinatal HIV prevention","volume":"375","author":"Fowler","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jcv.2019.06.003_bib0035","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization. June 2013","author":"World Health Organization","year":"2013"},{"key":"10.1016\/j.jcv.2019.06.003_bib0040","unstructured":"World Health Organization, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. World Health Organization. Available online: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/208825\/97892?sequence=1. (Accessed on 11 December 2018)."},{"issue":"September (Suppl. 4)","key":"10.1016\/j.jcv.2019.06.003_bib0045","first-page":"1","article-title":"British HIV Association guidelines for the management of HIV infection in pregnant women 2012 (2014 interim review)","volume":"15","author":"de Ruiter","year":"2014","journal-title":"HIV Med."},{"key":"10.1016\/j.jcv.2019.06.003_bib0050","series-title":"Guidelines Version 9.0","author":"European AIDS Clinical Society","year":"2017"},{"key":"10.1016\/j.jcv.2019.06.003_bib0055","year":"2019"},{"key":"10.1016\/j.jcv.2019.06.003_bib0060","series-title":"Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living With HIV","author":"US Department of Health and Human Services","year":"2017"},{"key":"10.1016\/j.jcv.2019.06.003_bib0065","series-title":"National Consolidated Guidelines for the Prevention of Mother-to-child Transmission of HIV (PMTCT) and the Management of HIV in Children, Adolescents and Adults","author":"South Africa National Department of Health","year":"2015"},{"key":"10.1016\/j.jcv.2019.06.003_bib0070","series-title":"The South African Antiretroviral Treatment Guidelines","author":"South Africa National Department of Health","year":"2013"},{"key":"10.1016\/j.jcv.2019.06.003_bib0075","series-title":"Universal Test and Treat","author":"South African National Department of Health","year":"2016"},{"issue":"October (10)","key":"10.1016\/j.jcv.2019.06.003_bib0080","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3018(17)30109-1","article-title":"Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV\/AIDS: a systematic review and network meta-analysis","volume":"4","author":"Kanters","year":"2017","journal-title":"Lancet HIV"},{"issue":"August (8)","key":"10.1016\/j.jcv.2019.06.003_bib0085","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/S2352-3018(17)30065-6","article-title":"Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial","volume":"4","author":"Paton","year":"2017","journal-title":"Lancet HIV"},{"issue":"January (2)","key":"10.1016\/j.jcv.2019.06.003_bib0090","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3851\/IMP2010","article-title":"Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients","volume":"17","author":"Barth","year":"2012","journal-title":"Antivir. Ther."},{"issue":"August (5)","key":"10.1016\/j.jcv.2019.06.003_bib0095","first-page":"711","article-title":"Viral suppression following switch to second-line antiretroviral therapy: associations with nucleoside reverse transcriptase inhibitor resistance and subtherapeutic drug concentrations prior to switch","volume":"209","author":"Johnston","year":"2013","journal-title":"J. Infect. Dis."},{"issue":"March (11)","key":"10.1016\/j.jcv.2019.06.003_bib0100","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/infdis\/jis261","article-title":"Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa","volume":"205","author":"Sigaloff","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jcv.2019.06.003_bib0105","series-title":"Stanford University HIV Drug Resistance Database","year":"2019"},{"key":"10.1016\/j.jcv.2019.06.003_bib0110","series-title":"National Guidelines on Anti-retroviral Therapy","author":"Namibian Ministry of health and social services","year":"2016"},{"key":"10.1016\/j.jcv.2019.06.003_bib0115","series-title":"Consolidated Guidelines for Prevention and Treatment of HIV in Uganda","author":"Ugandan Ministry of health","year":"2016"},{"issue":"October (10)","key":"10.1016\/j.jcv.2019.06.003_bib0120","article-title":"HIV-1 variants and drug resistance in pregnant women from bata (Equatorial Guinea): 2012-2013","volume":"11","author":"Alvarez","year":"2016","journal-title":"PLoS One"},{"issue":"August (13)","key":"10.1016\/j.jcv.2019.06.003_bib0125","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1097\/QAD.0000000000001569","article-title":"HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens","volume":"31","author":"Poppe","year":"2017","journal-title":"AIDS"},{"issue":"December (1)","key":"10.1016\/j.jcv.2019.06.003_bib0130","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12879-018-3087-8","article-title":"Factors affecting adherence to antiretroviral therapy among pregnant women in the Eastern Cape, South Africa","volume":"18","author":"Adeniyi","year":"2018","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.jcv.2019.06.003_bib0135","series-title":"South African Statistics","author":"Statistics South Africa","year":"2011"},{"key":"10.1016\/j.jcv.2019.06.003_bib0140","series-title":"Guidelines for Surveillance of HIV Drug Resistance","author":"World Health Organization","year":"2003"},{"issue":"January (1)","key":"10.1016\/j.jcv.2019.06.003_bib0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1089\/aid.2005.21.103","article-title":"Characterization of human immunodeficiency virus type 1 from a previously unexplored region of South Africa with a high HIV prevalence","volume":"21","author":"Bessong","year":"2005","journal-title":"AIDS Res. Hum. Retroviruses"},{"issue":"January (19)","key":"10.1016\/j.jcv.2019.06.003_bib0150","doi-asserted-by":"crossref","first-page":"3797","DOI":"10.1093\/bioinformatics\/bti607","article-title":"An automated genotyping system for analysis of HIV-1 and other microbial sequences","volume":"21","author":"De Oliveira","year":"2005","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.jcv.2019.06.003_bib0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000331998","article-title":"The HIVdb system for HIV-1 genotypic resistance interpretation","volume":"55","author":"Tang","year":"2012","journal-title":"Intervirology"},{"key":"10.1016\/j.jcv.2019.06.003_bib0160","unstructured":"South Africa global AIDS response progress report (GARPR) Available online: http:\/\/sanac.org.za\/wp-content\/uploads\/2016\/06\/GARPR_report-high-res-for-print-June-15-2016.pdf. (Accessed on 3 December 2012)."},{"issue":"May (5)","key":"10.1016\/j.jcv.2019.06.003_bib0165","doi-asserted-by":"crossref","first-page":"e0178297","DOI":"10.1371\/journal.pone.0178297","article-title":"Decreased emergence of HIV-1 drug resistance mutations in a cohort of Ugandan women initiating option B+ for PMTCT","volume":"12","author":"Machnowska","year":"2017","journal-title":"PLoS One"},{"issue":"May (22)","key":"10.1016\/j.jcv.2019.06.003_bib0170","doi-asserted-by":"crossref","first-page":"8000","DOI":"10.1073\/pnas.0503233102","article-title":"Resting naive CD4+ T cells are massively infected and eliminated by X4-tropic simian\u2013human immunodeficiency viruses in macaques","volume":"102","author":"Nishimura","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.jcv.2019.06.003_bib0175","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4314\/ejhd.v25i1.69853","article-title":"The pattern of immunologic and virologic responses to Highly Active Antiretroviral Treatment (HAART): does success bring further challenges?","volume":"25","author":"Misgena","year":"2011","journal-title":"Ethiop. J. Health Dev."},{"issue":"July (11)","key":"10.1016\/j.jcv.2019.06.003_bib0180","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1097\/QAD.0000000000000261","article-title":"Drug resistance among newly-diagnosed HIV-infected children in the era of more efficacious antiretroviral prophylaxis","volume":"28","author":"Kuhn","year":"2014","journal-title":"AIDS"},{"issue":"1","key":"10.1016\/j.jcv.2019.06.003_bib0185","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4102\/sajhivmed.v19i1.751","article-title":"Similar HIV protection from four weeks of zidovudine versus nevirapine prophylaxis among formula-fed infants in Botswana","volume":"19","author":"Powis","year":"2018","journal-title":"South. Afr. J. HIV Med."},{"issue":"January (1)","key":"10.1016\/j.jcv.2019.06.003_bib0190","doi-asserted-by":"crossref","first-page":"18567","DOI":"10.7448\/IAS.16.1.18567","article-title":"Non\u2010nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability","volume":"16","author":"Usach","year":"2013","journal-title":"J. Int. AIDS Soc."},{"issue":"July (7)","key":"10.1016\/j.jcv.2019.06.003_bib0195","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nm0796-760","article-title":"Ordered accumulation of mutations in HIV protease confers resistance to ritonavir","volume":"2","author":"Molla","year":"1996","journal-title":"Nat. Med."}],"container-title":["Journal of Clinical Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219301416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1386653219301416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T20:51:24Z","timestamp":1663707084000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1386653219301416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":39,"alternative-id":["S1386653219301416"],"URL":"https:\/\/doi.org\/10.1016\/j.jcv.2019.06.003","relation":{},"ISSN":["1386-6532"],"issn-type":[{"value":"1386-6532","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HIV-1 drug resistance surveillance among parturient women on anti-retroviral therapy in the Eastern Cape, South Africa: Implications for elimination of mother-to-child transmission","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Virology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcv.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}